Summary
AbbVie Inc. reported strong financial performance for the nine months ended September 30, 2021, with net revenues reaching $41.3 billion, a 29.3% increase year-over-year, significantly boosted by the acquisition of Allergan. Diluted earnings per share (EPS) for the period were $4.19. The company demonstrated robust operating cash flow of $17.7 billion, underscoring its financial strength and operational efficiency. The report highlights the continued growth of AbbVie's immunology portfolio, with Skyrizi and Rinvoq showing substantial revenue increases. While Humira's global sales saw a modest increase, its U.S. performance remained strong, though partially offset by newer immunology drugs. The company also noted significant revenue contributions from its hematologic oncology products, Imbruvica and Venclexta, and its aesthetics and neuroscience franchises, largely benefiting from the Allergan integration and market recovery post-COVID-19. AbbVie also reaffirmed its commitment to returning value to shareholders through dividends and share repurchases.
Financial Highlights
56 data points| Revenue | $14.34B |
| Cost of Revenue | $4.39B |
| Gross Profit | $9.95B |
| SG&A Expenses | $3.08B |
| Operating Expenses | $10.04B |
| Operating Income | $4.31B |
| Interest Expense | $596.00M |
| Net Income | $3.18B |
| EPS (Basic) | $1.78 |
| EPS (Diluted) | $1.78 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.78B |
Key Highlights
- 1AbbVie reported a 29.3% increase in net revenues to $41.3 billion for the first nine months of 2021, driven largely by the Allergan acquisition and growth in key therapeutic areas.
- 2Diluted EPS for the nine months ended September 30, 2021, was $4.19, reflecting improved profitability and operational leverage.
- 3The immunology portfolio, particularly Skyrizi and Rinvoq, experienced substantial revenue growth (92.0% and >100.0% respectively), indicating strong market adoption.
- 4Humira's U.S. sales grew 8.1%, while international sales declined 13.9% due to biosimilar competition, highlighting a mixed performance for the flagship product.
- 5Aesthetics and Neuroscience segments, significantly enhanced by the Allergan acquisition, showed robust growth, with products like Botox Cosmetic and Botox Therapeutic performing strongly.
- 6Operating cash flow remained strong at $17.7 billion for the nine-month period, providing ample financial flexibility.
- 7The company continued its capital return program, paying $6.9 billion in dividends and repurchasing $550 million in shares during the first nine months of 2021.